CatalystFDA/Bio

ULTRAGENYX PHARMACEUTICAL INC. (RARE) DISCUSSES FDA APPROVAL OF GENE THERAPY FOR GLYCOGEN STORAGE DISEASE TYPE 1A TRANSCRIPT - SEEKINGALPHA

FDA approval catalyst for RARE gene therapy targeting glycogen storage disease 1A.

What changed

FDA approval catalyst for RARE gene therapy targeting glycogen storage disease 1A.

Why it matters

FDA approval catalyst for RARE gene therapy targeting glycogen storage disease 1A. — impact context not separately stored; see What changed.

Sources